# US 2025/0154567 A1 · Spatially encoded biological assays

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154567 A1
- Document ID: US20250154567A1
- Status: Published application
- Kind: A1
- Application number: 19/021,991
- Filed: 2025-01-15
- Published: 2025-05-15
- Earliest claimed: 2010-04-05
- Assignees: Prognosys Biosciences, Inc.
- Applicants: Prognosys Biosciences, Inc.
- Inventors: Mark S. Chee
- Web page: https://patentgrep.com/patent/US20250154567A1

## CPC

- C12Q 1/6837: using probe arrays or probe chips (C12Q1/6874 takes precedence)
- B01L 3/502715: {characterised by interfacing components, e.g. fluidic, electrical, optical or mechanical interfaces}
- C12Q 1/68: involving nucleic acids
- C12Q 1/6804: Nucleic acid analysis using immunogens (immunoassay G01N33/53)
- C12Q 1/6809: Methods for determination or identification of nucleic acids involving differential detection
- C12Q 1/6834: Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q 1/6841: In situ hybridisation
- C12Q 1/6869: Methods for sequencing
- C12Q 1/6874: involving nucleic acid arrays, e.g. sequencing by hybridisation
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C40B 30/04: by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
- C40B 60/04: Integrated apparatus specially adapted for both screening libraries and identifying library members
- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- G01N 33/543: with an insoluble carrier for immobilising immunochemicals
- G01N 33/54366: {Apparatus specially adapted for solid-phase testing}
- G01N 33/6845: {Methods of identifying protein-protein interactions in protein mixtures}
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- C12Q 1/6858: Allele-specific amplification
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- G01N 2458/10: Oligonucleotides as tagging agents for labelling antibodies
- G01N 2458/40: Rare earth chelates
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- B01L: CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

## Claims

### Claim 1

A method of detecting a target biological molecule in a tissue sample, comprising:
(a) providing a substrate comprising: (i) a first plurality of nucleic acid molecules each having a capture sequence and (ii) a second plurality of nucleic acid molecules each having a sequence corresponding to a location on the substrate;
(b) placing the tissue sample on the substrate;
(c) capturing the target biological molecule from the tissue sample onto a nucleic acid molecule of the first plurality of nucleic acid molecules using the capture sequence; and
(d) generating a nucleic acid molecule that includes: (i) a sequence of the captured target biological molecule and (ii) a sequence of the second plurality of nucleic acid molecules corresponding to the location of the target biological molecule in the tissue sample.
